Amylyx Pharmaceuticals (AMLX) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Xeris Biopharma (XERS) has outperformed Amylyx Pharmaceuticals (AMLX) over the past year, gaining 148.5% versus a gain of 77.4%. Amylyx Pharmaceuticals is the larger company by market cap ($3.35 billion vs $3.10 billion), about 1.1 times the size, while Xeris Biopharma is growing revenue faster (+43.7% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | XERS |
|---|---|---|
| Share price | $26.02 | $16.97 |
| Market cap | $3.35B | $3.10B |
| 1-day change | -0.69% | +2.11% |
| YTD return | +115.40% | +116.18% |
| 1-year return | +77.37% | +148.46% |
| 5-year return | — | +682.03% |
| Forward P/E | — | 63.64 |
| EPS (TTM) | $-1.43 | $-0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $291.85M |
| Revenue growth (YoY) | -100.00% | +43.72% |
| Net income (latest FY) | $-144.74M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $41.14 | $17.28 |
| 52-week low | $10.83 | $5.25 |
| Distance from 52-week high | -36.75% | -1.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.26% | +1.89% |
| Average volume | 1.53M | 2.86M |
| Shares outstanding | 128.56M | 182.70M |
| Employees | 136 | 435 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XERS has outperformed AMLX by 71.1 percentage points over the past year.
- Xeris Biopharma grew revenue faster in its latest fiscal year (+43.72% vs -100.00%).
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees
AMLX vs XERS FAQ
Which is bigger, Amylyx Pharmaceuticals or Xeris Biopharma?
Amylyx Pharmaceuticals (AMLX) is larger, with a market capitalization of $3.35B compared with $3.10B for Xeris Biopharma (XERS).
Which stock has performed better over the past year, AMLX or XERS?
XERS returned +148.46% over the past 12 months, compared with +77.37% for AMLX (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Xeris Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.